Connect your AI

Kymera Therapeutics KYMR Debt Issuance Costs

Debt Issuance Costs at other companies

TG TherapeuticsTGTX

$2.6M—

Other financials

Income statement

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfFinancingCosts.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kymera Therapeutics's debt issuance costs?: Kymera Therapeutics (KYMR) reported debt issuance costs of $425K in Q1 2026.
How has Kymera Therapeutics's debt issuance costs changed year-over-year?: Kymera Therapeutics's debt issuance costs increased by 53.4% year-over-year, from $277K to $425K.
What is the long-term trend for Kymera Therapeutics's debt issuance costs?: Over 3 years (2021 to 2025), Kymera Therapeutics's debt issuance costs has grown at a 20.7% compound annual growth rate (CAGR), from $849K to $1.49M.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.